Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM


The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. Sonis ST . Oral mucositis. Anti-Cancer Drugs 2011; 22: 607–612.

    CAS  Article  Google Scholar 

  2. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.

    CAS  Article  Google Scholar 

  3. Blijlevens N, de Chateau M, Krivan G, Rabitsch W, Szomor A, Pytlik R et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden. Bone Marrow Transplant 2012; 48: 966–971.

    Article  Google Scholar 

  4. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2013; 48: 99–104.

    CAS  Article  Google Scholar 

  5. Johansson JE, Hasseus B, Johansson P, Eklof C, Ohman D, Stockelberg D . Gut protection by palifermin during autologous haematopoietic SCT. Bone Marrow Transplant 2009; 43: 807–811.

    CAS  Article  Google Scholar 

  6. Blijlevens NM, Lutgens LC, Schattenberg AV, Donnelly JP . Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193–196.

    CAS  Article  Google Scholar 

  7. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP . Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120: 834–844.

    CAS  Article  Google Scholar 

  8. Cancer Therapy Evaluation Program NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Online Instructions and Guidelines. . Accessed May 19, 2009.

  9. Costa SF, Barone AA, Miceli MH, van der Heijden IM, Soares RE, Levin AS et al. Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study. Am J Infect Control 2006; 34: 36–40.

    Article  Google Scholar 

  10. Kennedy HF, Morrison D, Kaufmann ME, Jackson MS, Bagg J, Gibson BE et al. Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient. J Med Microbiol 2000; 49: 367–370.

    CAS  Article  Google Scholar 

  11. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST . The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275–2281.

    CAS  Article  Google Scholar 

  12. Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ . Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplant 2008; 42: 345–349.

    CAS  Article  Google Scholar 

  13. Van der Velden WJ, Blijlevens NM, Feuth T, Donnelly JP . Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplant 2009; 43: 55–60.

    CAS  Article  Google Scholar 

  14. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, Uren A, Welniak LA, Murphy WJ et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96: 4350–4356.

    CAS  PubMed  Google Scholar 

  15. Ellison CA, Makar BM, Wiseman JM, Gheorghiu I, Taniguchi M, Gartner JG . Palifermin mediates immunoregulatory effects in addition to its cytoprotective effects in mice with acute graft-versus-host disease. J Clin Immunol 2008; 28: 600–615.

    CAS  Article  Google Scholar 

  16. Barazzone C, Donati YR, Rochat AF, Vesin C, Kan CD, Pache JC et al. Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol 1999; 154: 1479–1487.

    CAS  Article  Google Scholar 

  17. Yildirim AO, Muyal V, John G, Müller B, Seifart C, Kasper M et al. Palifermin induces alveolar maintenance programs in emphysematous mice. Am J Respir Crit Care Med 2010; 181: 705–717.

    CAS  Article  Google Scholar 

Download references


We are indebted to Amgen Netherlands for donating an unrestricted grant.

Author information

Authors and Affiliations


Corresponding author

Correspondence to A H E Herbers.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

AHEH and NMAB conceived the study, wrote and reviewed the manuscript. JPD and WJFMvdV helped to draft the manuscript. AFJdH performed the statistical analysis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Herbers, A., van der Velden, W., de Haan, A. et al. Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM. Bone Marrow Transplant 49, 8–10 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links